Search
CTS-21166
go.drugbank.com/drugs/DB06073InvestigationalIn 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability … , and oral availability; all of these have met the requirements of an ideal oral drug candidate.
Pentamidine
go.drugbank.com/drugs/DB00738ApprovedInvestigationalAntiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients.
Barnidipine
go.drugbank.com/drugs/DB09227Investigationalafter a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [A7842]. … It is available in modified-release oral tablets under the brand name Vasexten to be taken once daily in the morning.
Bucrylate
go.drugbank.com/drugs/DB19727ExperimentalBucrylate is a small molecule drug. Bucrylate has a monoisotopic molecular weight of 153.08 Da.
Categories: Compounds used in a research, industrial, or household settingAvdoralimab
go.drugbank.com/drugs/DB16392InvestigationalAvdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
SAR443122
go.drugbank.com/drugs/DB16492InvestigationalSAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. … Additionally, NCT04781816, which was completed with results, focused on patients with cutaneous lupus erythematosus.
Synonyms: 1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-1H-1,2,4-TRIAZOLE-5-CARBOXAMIDEISF402
go.drugbank.com/drugs/DB06315ExperimentalISF402 is an investigational peptide tetramer which helps dispersal of insulin via zinc chelation, therefore allowing insulin hexamers to break free.
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalXTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein.